Profound Medical Corp. (PROF) News

Profound Medical Corp. (PROF): $14.82

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add PROF to Watchlist
Sign Up

Filter PROF News Items

PROF News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PROF News Highlights

  • PROF's 30 day story count now stands at 5.
  • Over the past 23 days, the trend for PROF's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • CPT and TALK are the most mentioned tickers in articles about PROF.

Latest PROF News From Around the Web

Below are the latest news stories about PROFOUND MEDICAL CORP that investors may wish to consider to help them evaluate PROF as an investment opportunity.

Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases

TORONTO, June 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, with sponsorship and support from multiple physician specialty societies, the American Medical Association (“AMA”) has established three new Current Procedural Terminology (“CPT®’) Category 1 codes for MRI-Monitored

Yahoo | June 2, 2023

Profound Medical Announces Upcoming Investor Events

TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announces the following investor events in June: PRO-Talk Episode 5, “Unlocking the Potential of TULSA-PRO®”: Profound will be hosting a live webinar on Tuesday, June 6, 2023 at 6:00 p.m. ET, during which the following esteemed TUSLA-PRO®

Yahoo | May 30, 2023

Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference

TORONTO, May 18, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management will participate in A.G.P.’s Virtual Healthcare Conference on Wednesday, May 24, 2023. The event will consist of one-on-one investor meetings. Due to the format of the event, no webcast will be available. About P

Yahoo | May 18, 2023

Profound Medical Annual and Special Meeting of Shareholders Voting Results

TORONTO, May 17, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 13,437,920 common shares, representing 63.64% of the common shares outstanding, were represented in person and by proxy at the Meeting. All of the matters put forward before the shareholders, as set out in the Company’s management informa

Yahoo | May 17, 2023

Profound Medical Announces First Quarter 2023 Financial Results

TORONTO, May 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reportin

Yahoo | May 10, 2023

TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting

– Presentations reinforce the safety, efficacy and durability of the TULSA procedure, further supporting its potential as a mainstream, whole gland or focal treatment for prostate disease – – FARP study provides Level 1 evidence that focal therapy with TULSA has a lower complication rate compared to RALP – TORONTO, May 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets custo

Yahoo | May 1, 2023

Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in t

Yahoo | April 19, 2023

Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre. Th

Yahoo | April 19, 2023

Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results

Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSATORONTO, March 07, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2022. Unless specified otherwise, all amounts in this pres

Yahoo | March 7, 2023

Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 9:10 a.m. Eastern Time. The presentation will be br

Yahoo | March 1, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6843 seconds.